Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sharper MRI could Fine-Tune brain surgery for Parkinson's

NCT ID NCT02800460

Knowledge-focused Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests whether a new, high-field 3T MRI technique can more accurately pinpoint the subthalamic nucleus — a key brain area targeted during deep brain stimulation (DBS) for Parkinson's disease. Researchers will compare images from the new method with standard 1.5T MRI in 105 Parkinson's patients who are candidates for DBS. The goal is to improve surgical precision, which could lead to better symptom relief and fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could improve the precision of deep brain stimulation surgery for Parkinson's, potentially leading to better symptom control and fewer side effects.
What could go wrong
This is an early imaging study, not a treatment trial. The new MRI method may not prove more accurate than current techniques, and any benefit to patients remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

105 people

The number who actually took part.

Started

Oct 2016

Finished

Nov 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of idiopathic Parkinson's disease (according to the criteria of the "United Kingdom Parkinson's Disease Society Brain Bank"; * Age between 18 and 70 years * motor complications in the form of fluctuations in motor state or induced dyskinesias dopaminergic therapy, despite optimal medical treatment; * Excellent responsiveness to levodopa (improved motor UPDRS score of higher than 50% during the acute test with levodopa) * People who voluntarily accepted and intelligently participate in the study (signing a written consent) * Patient receiving social health insurance Exclusion Criteria: * Patients carry an apomorphine pump used in single and continuous treatment; * scalable psychiatric pathology; * Dementia (MMS \<24/30); * Existence of against-indications to MRI (cardiac or neural stimulator, ferromagnetic surgical clips, implants and metal objects, intraocular foreign bodies, pregnancy, claustrophobia). * Persons under guardianship, trusteeship or any other administrative or judicial deprivation of rights and freedom

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • GHPS

    Paris, Île-de-France Region, 75651, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.